Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03180398 · ClinicalTrials.gov registry record · NA
Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients
A NA study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT03180398: Clinical Trial NA study, sponsored by Henry Ford Health System.
NCT03180398 is a NA study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03180398, a NA study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a pilot study of implement multi-parametric MR imaging for organ delineation and tumor response assessment of prostate cancer patients being treated with radiation therapy.
Primary Outcome
Identify the radiomics features selected from multimodal MRI to distinguish the dominant lesions from the normal tissues within the prostate. Track the changes of these features with longitudinal MRI scans to identify its correlation with the local control.
Interventions
- DEVICE Multiparametric MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2022-02-15 |
| Phase | NA |
Why NCT03180398 stopped before completion
NCT03180398 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Multiparametric MRI is the first listed.
NCT03180398 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03180398 about?
NCT03180398 is a clinical study titled "Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients". This is a pilot study of implement multi-parametric MR imaging for organ delineation and tumor response assessment of prostate cancer patients being treated with radiation therapy.
What is the current status of trial NCT03180398?
This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2017-10-04. Estimated completion is 2022-02-15.
What interventions are being tested in trial NCT03180398?
The interventions under investigation include: Multiparametric MRI (DEVICE).
Who is sponsoring clinical trial NCT03180398?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03180398's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI